LZTR1

Across TCGA pan-cancer cohorts, LZTR1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LZTR1 data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher LZTR1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LZTR1 expression acts as an unfavorable survival marker.

GBM, LUAD, and HNSC are the cancer types where LZTR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.278	0.484	.002	24	view →
LUAD	OS	Tertile	All	0.376	1.000	<.001	12	view →
HNSC	OS	Tertile	IV	0.649	0.939	.003	9	view →
PDAC	DFS	Median	All	0.748	0.864	.014	4	view →
UCEC	DFS	Median	III,IV	0.256	0.852	.016	4	view →
CCRCC	DFS	Quartile	III,IV	0.222	0.887	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LZTR1–GBM (DFS)

Open the GBM breakdown →